Clough Capital Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Clough Capital Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-42,200	Closed	-$3.28M	–	181
2022 Q4	$3.28M	Buy	+42,200	New	+$3.11M	0.33%	76
2022 Q2	–	Sell	-34,700	Closed	-$2.77M	–	116
2022 Q1	$2.77M	Sell	34,700 -35,100	-50%	-$2.69M	0.21%	81
2021 Q4	$5.37M	Sell	69,800 -23,300	-25%	-$1.73M	0.36%	63
2021 Q3	$6.78M	Buy	+93,100	New	+$6.94M	0.41%	62
2021 Q1	–	Sell	-330,400	Closed	-$22M	–	166
2020 Q4	$22M	Buy	+330,400	New	+$21.2M	1.56%	24

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VAS

Valicenti Advisory Services Elmira, New York $530M AUM 46.5% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Clough Capital Partners's PPH Position: Q1 2023 in Review

Clough Capital Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2023, closing a stake of 42,200 shares — an estimated $3.28M sold.

Clough Capital Partners first reported a position in PPH in Q4 2020 and held it in 5 quarters. The position peaked at $22M in Q4 2020. 106 funds tracked by Wall St. Rank hold PPH as of Q1 2023.

Clough Capital Partners reported no remaining VanEck Pharmaceutical ETF position as of Q1 2023 after selling out during the quarter.
Clough Capital Partners sold 42,200 VanEck Pharmaceutical ETF shares in Q1 2023, an estimated $3.28M.
Clough Capital Partners first reported a position in VanEck Pharmaceutical ETF in Q4 2020 and held it in 5 quarters.
Clough Capital Partners's VanEck Pharmaceutical ETF position peaked at $22M in Q4 2020.
106 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2023.

Based on Clough Capital Partners's 13F filing for Q1 2023, filed 15 May 2023.